Applications for phase three of the Pathway Transformation Fund (PTF) are now open.
The fund supports NHS organisations increase their adoption of the 2020/21 Rapid Uptake Products RUPs, which are:
- Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors
- Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
- Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab
The PTF can help providers overcome practical obstacles to introducing these products, such as:
- Support set-up costs such as training and accreditation of staff;
- Pathway redesign and/or business support expertise;
- Providing funding for specialist nurses and clinical staff needed to implement a new part of the procedure; and
- Covering double running costs
- Capital costs.
NHS organisations will be able to submit applications for PTF until 12 noon, 30 April 2021. Applications should be developed and submitted with the support of your local AHSN RUP lead – please email info@innovationagencynwc.nhs.uk for further details.
News and blogs >
Accelerator aims to boost established innovations Read more
Momentum accelerator launches second year to provide a boost to existing heath innovations
Business support drives economic growth Read more
Health Innovation North West Coast has helped create or safeguard 59 jobs while securing £17.7m of investment for companies in our region in the last year.
A step forward in knee pain treatment Read more
Patients in Merseyside are benefiting from life-changing relief from knee pain and osteoarthritis thanks to a ground-breaking medical device.
Annual Review is published Read more
We are proud to publish our Annual Review 2025.